Introduction-We are developing 18 F-labeled 6-fluoro-6-deoxy-D-glucose ([ 18 F]6FDG) as a tracer of glucose transport. As part of this process it is important to characterize and quantify putative metabolites. In contrast to the ubiquitous PET tracer 18 F-labeled 2-fluoro-2-deoxy-Dglucose ([ 18 F]2FDG) which is phosphorylated and trapped intracellularly, the substitution of fluorine for a hydroxyl group at carbon 6 in [ 18 F]6FDG should prevent its phosphorylation. Consequently, [ 18 F]6FDG has the potential to trace the transport step of glucose metabolism without the confounding effects of phosphorylation and subsequent steps of metabolism. Herein the focus is to determine whether, and the degree to which, [ 18 F]6FDG remains unchanged following intravenous injection.Methods-Biodistribution studies were performed using 6FDG labeled with 18 F as well as the longer-lived radionuclides 3 H and 14 C. Tissues were harvested at 1, 6, and 24 h following intravenous administration and radioactivity was extracted from the tissues and analyzed using a combination of ion exchange columns, high-performance liquid chromatography, and chemical reactivity.Results-At the 1 h time-point, the vast majority of radioactivity in the liver, brain, heart, skeletal muscle, and blood was identified as 6FDG. At the 6-and 24-h time-points there was evidence of a minor amount of radioactive materials that appeared to be 6-fluoro-6-deoxy-Dsorbitol and possibly 6-fluoro-6-deoxy-D-gluconic acid.
Conclusion-On